Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Apricus Biosciences has announced that Takeda Pharmaceuticals International, the company's partner in the UK, has accepted the first shipment of Vitaros, Apricus' novel topical on-demand treatment for erectile dysfunction (ED).
Subscribe to our email newsletter
Apricus CEO Richard Pascoe noted that the company is excited to have completed the first of several product shipments of Vitaros to different territories in Europe in 2014.
"With the commercial availability of Vitaros® in the United Kingdom, Takeda is in a position to finalize its pre-launch activities in an effort to be the first Vitaros® commercial partner to offer an on demand topical cream treatment for men with erectile dysfunction," Pascoe added.
In September 2012, Apricus and Takeda entered into an exclusive license agreement to market Vitaros in the UK. The product received regulatory approval in Europe in June of 2013 and in August of 2013, Apricus received the national phase approval to have the product marketed in the UK.
Earlier 2014, Apricus received commercial product orders from certain of its partners, including Takeda, and commenced manufacturing of product for these partners through its contract manufacturer in Canada.
In addition to manufacturing commercial product for its partners, Apricus will also provide clinical support for its partners’ pre-commercialization activities in an effort to facilitate a consistent launch of Vitaros throughout 2014.